161 related articles for article (PubMed ID: 34793609)
21. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
22. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
23. Novel TGFβ Inhibitors Ameliorate Oral Squamous Cell Carcinoma Progression and Improve the Antitumor Immune Response of Anti-PD-L1 Immunotherapy.
Ludwig N; Wieteska Ł; Hinck CS; Yerneni SS; Azambuja JH; Bauer RJ; Reichert TE; Hinck AP; Whiteside TL
Mol Cancer Ther; 2021 Jun; 20(6):1102-1111. PubMed ID: 33850003
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 degradation pathway and immunotherapy for cancer.
Gou Q; Dong C; Xu H; Khan B; Jin J; Liu Q; Shi J; Hou Y
Cell Death Dis; 2020 Nov; 11(11):955. PubMed ID: 33159034
[TBL] [Abstract][Full Text] [Related]
25. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
[TBL] [Abstract][Full Text] [Related]
26. The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial.
Metropulos AE; Munshi HG; Principe DR
EBioMedicine; 2022 Dec; 86():104380. PubMed ID: 36455409
[TBL] [Abstract][Full Text] [Related]
27. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.
Principe DR; Park A; Dorman MJ; Kumar S; Viswakarma N; Rubin J; Torres C; McKinney R; Munshi HG; Grippo PJ; Rana A
Mol Cancer Ther; 2019 Mar; 18(3):613-620. PubMed ID: 30587556
[TBL] [Abstract][Full Text] [Related]
28. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
[TBL] [Abstract][Full Text] [Related]
29. Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
Miller KM; Friedman CF
Clin Cancer Res; 2022 Dec; 28(24):5238-5240. PubMed ID: 35947045
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in the clinical development of immune checkpoint blockade therapy.
Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
[TBL] [Abstract][Full Text] [Related]
31. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
[TBL] [Abstract][Full Text] [Related]
32. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
33. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types.
Wilkins JJ; Vugmeyster Y; Dussault I; Girard P; Khandelwal A
Adv Ther; 2019 Sep; 36(9):2414-2433. PubMed ID: 31278692
[TBL] [Abstract][Full Text] [Related]
35. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Zhang J; Dang F; Ren J; Wei W
Trends Biochem Sci; 2018 Dec; 43(12):1014-1032. PubMed ID: 30287140
[TBL] [Abstract][Full Text] [Related]
36. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
[TBL] [Abstract][Full Text] [Related]
37. TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy.
Yi M; Li T; Niu M; Wu Y; Zhao Z; Wu K
Front Immunol; 2022; 13():1061394. PubMed ID: 36601124
[TBL] [Abstract][Full Text] [Related]
38. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
[TBL] [Abstract][Full Text] [Related]
39. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
40. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]